260 related articles for article (PubMed ID: 23570154)
1. [Oxaliplatin in colorectal carcinoma: from palliation to cure].
Arnheim K
Onkologie; 2004 Aug; 27 Suppl 1():2-11. PubMed ID: 23570154
[No Abstract] [Full Text] [Related]
2. [Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
Krankenpfl J; 2004; 42(7-10):234. PubMed ID: 15675396
[No Abstract] [Full Text] [Related]
3. FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Ottaiano A; Nasti G; Cassata A; De Stefano A; Caraglia M; Avallone A
Cancer Lett; 2017 Nov; 408():71-72. PubMed ID: 28844712
[No Abstract] [Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
5. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
7. X-ACT: an important step on an unfinished journey.
Maughan T
Ann Oncol; 2012 Jul; 23(7):1655-8. PubMed ID: 22517823
[No Abstract] [Full Text] [Related]
8. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Allegra C; George T; Yothers G
J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
[No Abstract] [Full Text] [Related]
9. On 5-fluorouracil therapy of colorectal cancer.
Jensen SA
Dan Med J; 2013 Jul; 60(7):B4603. PubMed ID: 23809976
[No Abstract] [Full Text] [Related]
10. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Cassidy J
Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
[No Abstract] [Full Text] [Related]
11. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
[TBL] [Abstract][Full Text] [Related]
12. Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Teitelbaum UR; Haller DG
Nat Rev Clin Oncol; 2009 May; 6(5):250-1. PubMed ID: 19390547
[TBL] [Abstract][Full Text] [Related]
13. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H
J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286
[No Abstract] [Full Text] [Related]
14. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Klautke G; Fietkau R
Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194
[No Abstract] [Full Text] [Related]
15. Oxaliplatin: a welcome addition to our therapeutic armamentarium.
Chu E
Clin Colorectal Cancer; 2002 Aug; 2(2):72. PubMed ID: 12453318
[No Abstract] [Full Text] [Related]
16. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
17. Do we need oncology trials tailored for the elderly or frail?
Schmoll HJ
Lancet; 2011 May; 377(9779):1725-7. PubMed ID: 21601694
[No Abstract] [Full Text] [Related]
18. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
19. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
20. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
